Product Description
FLT3 (Fms-like tyrosine kinase 3), also known as CD135, is a member of the class III receptor tyrosine kinase (RTK) family that plays a pivotal role in hematopoietic stem and progenitor cell proliferation, differentiation, and survival, as well as in dendritic cell and B-cell development. FLT3 binds with high affinity to its ligand FLT3L (FLT3 ligand), leading to activation of downstream signaling pathways including RAS-MAPK, PI3K-AKT, and STAT5. Beyond its role in normal hematopoiesis and immune function, dysregulation of FLT3 signaling—through internal tandem duplication (ITD) mutations in the juxtamembrane domain or point mutations (e.g., D835, I836) in the tyrosine kinase domain—is closely associated with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and poor prognosis in hematological malignancies, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s FLT3 (D835Y) Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying FLT3 (D835Y) kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: FLT3 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the FLT3 kinase.
Data